Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
- ophthalmic artery
- ciliary body
- optics and refraction
- treatment other
- treatment lasers
We have previously reported on bilateral intra-arterial (IA) chemosurgery for bilateral retinoblastoma, or tandem therapy.1 While this allows both eyes to be treated during the same IA session, it also exposes the patient to twice the dose of chemotherapy (typically melphalan and topotecan). Even at the doses used for IA, the systemic levels of melphalan can be dose-limiting (melphalan may induce neutropenia at doses higher than 0.4 mg/kg). To obviate the need for melphalan dose restriction during tandem therapy, we report on the use of single agent carboplatin to the fellow eye.
Three children with bilateral retinoblastoma (all with Reese–Ellsworth group IVa in one eye and 2b in one fellow eye and 5a in two fellow eyes; International Classification, B: …
Funding This work was supported by The Fund for Ophthalmic Knowledge and the New York Community Trust.
Competing interests None.
Patient consent Obtained.
Ethics approval Ethics approval was provided by the Memorial Sloan Kettering Cancer Center.
Provenance and peer review Not commissioned; internally peer reviewed.